Format

Send to

Choose Destination
Neuropharmacology. 2014 May;80:95-102. doi: 10.1016/j.neuropharm.2014.01.038. Epub 2014 Jan 31.

Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?

Author information

1
Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Grisebachstr. 5, 37077 Göttingen, Germany; Research Group for Epigenetic Mechansims of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Grisebachstr. 5, 37077 Göttingen, Germany. Electronic address: afische2@gwdg.de.

Abstract

Alzheimer' s disease (AD) is the most common form of dementia causing an increasing emotional and economical burden to our societies. Although much progress has been made regarding the molecular mechanisms that underlie AD pathogenesis effective therapies are not available yet. The emerging field of neuroepigenetics has provided evidence that de-regulation of epigenetic processes play a role in AD. In this article we will critically review the primary research data that led to the hypothesis that targeting histone-modifying enzymes could be used to treat AD pathogenesis and address the question if the field is ready to translate such findings into clinical application.

KEYWORDS:

Alzheimer; Gene-expression; HDAC inhibitors; Histone-acetylation; Memomry

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center